1. Cure Duchenne is Pleased that Sarepta Therapeutics Plans to Submit NDA for Eteplirsen in First Half of 2014

    Posted on July 24, 20134:23 pm

      Sarepta Therapeutics announced today plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the first half of 2014 for the approval of eteplirsen, an exon skipping compound under development for the treatment of Duchenne muscular dystrophy. CureDuchenne, a leader in raising awareness and funding research to Read more »